Lupin Partners With Valorum to Push Armlupeg in the U.S. Market

Global pharma leader Lupin has taken a major step forward in the U.S. biosimilar market with a new exclusive licensing agreement for Armlupeg (pegfilgrastim-unne).

The company announced today that it has partnered with Valorum Biologics, a U.S.-based biosimilar specialist, to drive the product’s commercial launch and distribution across the country.

Under this deal, Valorum will handle the U.S. commercialization strategy for Armlupeg, bringing its specialty-market expertise to expand the drug’s reach. Lupin will continue to manufacture and supply the biosimilar while receiving an upfront licensing fee along with royalties tied to net sales.

Also Read: Navigating the New Era of Nitrosamine Compliance

“We are pleased to collaborate with Valorum to expand access to affordable treatment options for patients undergoing chemotherapy. This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines,” said Spiro Gavaris, president – US Generics, Lupin.

“We are excited to launch Armlupeg (pegfilgrastim-unne) in the US. Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise,” said Par S. Hyare, CEO of Valorum. “Crucially, we also look forward to providing another option for healthcare providers and patients, increasing access to this important treatment in oncology supportive care.”

Pegfilgrastim-unne is used to reduce the duration of neutropenia and lower the risk of febrile neutropenia in patients receiving chemotherapy.